CAMBRIDGE, Mass. / Aug 02, 2024 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under... Read More

CAMBRIDGE, Mass. / Jul 30, 2024 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) (“Court”) has issued an initial order (“Initial Order”) granting the company protection under the Companies’ Creditors Arrangement Act , R.S.C.... Read More

CAMBRIDGE, Mass. / Jun 25, 2024 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by... Read More

Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, was observed at week 6, after 2 doses of VBI-1901 The disease control rate (DCR) in the VBI-1901 study arm was 43% (n=3/7) compared to 0%... Read More

CAMBRIDGE, Mass. / May 22, 2024 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted... Read More

PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) announced in April ­– additional data expected mid-year and year-end 2024 Evaluation of novel mRNA-launched eVLP (MLE) platform technology underway... Read More

PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone Early data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) demonstrate encouraging separation of tumor response trends between VBI-1901 study arm... Read More

CAMBRIDGE, Mass. / Apr 11, 2024 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,272,728 of its common shares and warrants to purchase up to 2,272,728 common shares, at an... Read More

CAMBRIDGE, Mass. / Apr 09, 2024 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares (or pre-funded warrants in lieu thereof) of VBI at an offering price of $0.88 per common share (or per... Read More

Data highlighted in oral presentation at World Vaccine Congress 2024 on April 3, 2024 Early data from patients eligible for evaluation at week 12 show two observations of stable disease, indicating no tumor progression, in VBI-1901 treatment arm (n=2/5; 40% disease control rate [DCR]) By comparison, no tumor responses have been observed in the control arm to-date (n=0/6; 0% DCR), with all patients seeing a 2-8x increase in... Read More

VBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine (“MLE”) technology platform The partnership will direct CAD$28 million of funding remaining under the original CAD$56 million award to continue development of VBI’s two proprietary technology platforms In parallel, VBI’s MLE technology is under... Read More

VBI to receive up to $33 million in consideration, subject to achievement of certain activities, for: VBI’s manufacturing capabilities and certain related assets at Rehovot manufacturing facility Intellectual property for VBI-2601, VBI’s hepatitis B immunotherapeutic candidate Exclusive Asia Pacific (APAC), excluding Japan, license for development and commercialization of VBI-1901, VBI’s glioblastoma immunotherapeutic... Read More

CAMBRIDGE, Mass. / Nov 20, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients, were highlighted in a poster... Read More

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients Interim Phase 1 data announced for pan-coronavirus candidate, VBI-2901 Novel mRNA-launched eVLP platform technology announced CAMBRIDGE, Mass. / Nov 14, 2023 /... Read More

Preclinical data suggests novel mRNA-launched eVLPs (“MLE”) generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone In addition to immunologic benefits, new MLE technology enables manufacturing of particulate vaccines on an accelerated timeline, similar to other mRNA manufacturing timelines Based on encouraging data seen to date, MLE proprietary technology is under evaluation... Read More

First clinical data from a pan-coronavirus vaccine candidate Elicited high and sustained neutralizing responses against a panel of COVID-19 variants, including Wuhan, Delta, Beta, Omicron BA.5, as well as multiple animal coronaviruses including bat and pangolin variants Durability of protective titers maintained through interim data point at six months – substantially more persistent compared to published durability of... Read More

Multi-center, randomized, controlled, open-label study to enroll up to 60 patients with first recurrent GBM FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in the recurrent setting, following encouraging Phase 1/2a study results Interim data analysis expected mid-year 2024, subject to speed of enrollment CAMBRIDGE, Mass. / Sep 07, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV)... Read More

BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased seroconversion rate is strongly associated with BRII-179 (VBI-2601) treatment and correlates with the increased rate of HBsAg loss Safety findings are similar to those of PEG-IFNα and BRII-179 (VBI-2601) as previously reported CAMBRIDGE, Mass. / Sep 06, 2023 /... Read More

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis B collaboration with Brii Biosciences announced in July for $15 million upfront, including a $3 million equity investment, and up to $422 million in potential additional milestones plus double-digit royalties... Read More

CAMBRIDGE, Mass. / Jul 24, 2023 / Business Wire / VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public offering of common shares and accompanying common warrants to purchase common shares partially exercised their option to purchase an... Read More

PreHevbri ® is the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium Product to be launched via marketing and distribution partner, Valneva CAMBRIDGE, Mass. / Jul 19, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri ® [Hepatitis B... Read More

Approximately $21 million in gross proceeds from underwritten public offering and concurrent registered direct offering add to upfront payment from Brii Biosciences for a combined $33 million to be received by VBI CAMBRIDGE, Mass. / Jul 06, 2023 / Business Wire / VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of... Read More

CAMBRIDGE, Mass. / Jul 05, 2023 / Business Wire / VBI Vaccines Inc. ( NASDAQ: VBIV ) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public offering and a registered direct offering of its common shares and accompanying common warrants to purchase its common shares. VBI also intends... Read More

Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments, subject to near-term milestone achievements, including an equity investment of approximately $3 million VBI is eligible to receive up to $422 million in additional potential regulatory and commercial milestone payments,... Read More

CAMBRIDGE, Mass. / Jun 23, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 23, 2023 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by... Read More

PreHevbri ® is the only approved 3-antigen hepatitis B vaccine for adults in the U.K. Product to be launched via marketing and distribution partner, Valneva CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri ® [Hepatitis B vaccine (recombinant,... Read More

CAMBRIDGE, Mass. / Jun 07, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been... Read More

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHevbrio continues to broaden – now available at several U.S. retail pharmacy chains including Costco, RiteAid, and Walmart Therapeutic Hepatitis B: Initial Phase 2 study data announced, which suggest that the combination of VBI-2601 and an HBV siRNA has the potential to be a meaningful... Read More

CAMBRIDGE, Mass. / Apr 25, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change... Read More

VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 Cost-saving measures expected to reduce quarterly operating expenses and headcount by 30-35% VBI to effect a 1-for-30 reverse stock split of its issued and outstanding common shares – shares are expected to trade on the... Read More

CAMBRIDGE, Mass. / Mar 13, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2022. Jeff Baxter, VBI’s President and CEO commented: “The achievements of 2022, across our pipeline, set 2023 up for a strong... Read More

CAMBRIDGE, Mass. / Feb 23, 2023 / Business Wire / VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, VBI’s Chief Scientific Officer, will discuss the company’s hepatitis B (HBV) portfolio with covering analyst, Steven Seedhouse, Ph.D., from... Read More

OTTAWA, Ontario & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio ™ [3-antigen Hepatitis B Vaccine (Recombinant)] for active immunization against infection caused by all known subtypes of hepatitis B (HBV) virus in adults 18... Read More

CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus OSLO, Norway & CAMBRIDGE, Mass.--( BUSINESS WIRE )--The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the... Read More